Coleen Glessner serves as Executive Vice President of Quality and Ethics & Compliance at Emergent BioSolutions Inc., a global leader in developing and manufacturing vaccines and therapeutics for public health threats. In this pivotal role, she oversees the company's comprehensive quality assurance, regulatory compliance, ethics programs, and risk management initiatives, ensuring the integrity and safety of critical products like BioThrax and other biodefense countermeasures. Her leadership is instrumental in maintaining rigorous standards amid complex manufacturing operations and stringent FDA oversight. With more than 25 years in the biopharmaceutical industry, Glessner brings a wealth of expertise from her tenure at Pfizer Inc., where she spent over two decades in progressively senior quality and compliance positions. Notably, she served as Vice President of Quality Operations for Pfizer's Gene Therapy and Rare Disease business units, where she spearheaded global quality systems, led successful FDA inspections, and drove process improvements that enhanced operational efficiency and product reliability. Glessner's achievements include implementing enterprise-wide compliance frameworks that mitigated risks and fostered a culture of ethical excellence, earning her recognition for excellence in quality leadership. At Emergent, she has been key in navigating high-stakes regulatory landscapes, particularly during the COVID-19 response, while advancing sustainable quality practices that support the company's mission to protect life.